Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2023-2027

Report
154 Pages
July 2023
Region: Global
TechNavio
ID: 5547403

The Duchenne muscular dystrophy (DMD) therapeutics market is forecasted to grow by USD 2,397.67 mn during 2022-2027, accelerating at a CAGR of 21.2% during the forecast period. The report on the Duchenne muscular dystrophy (DMD) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet need among patients with Duchenne muscular dystrophy (DMD), increasing strategic alliances among market vendors, and availability of patient assistance programs.

The Duchenne muscular dystrophy (DMD) therapeutics market is segmented as below:

By Type

Biologics
Small molecules

By Distribution Channel

Offline
Online

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the strong pipeline of Duchenne muscular dystrophy (DMD) therapeutics as one of the prime reasons driving the Duchenne muscular dystrophy (DMD) therapeutics market growth during the next few years. Also, increasing research funding for Duchenne muscular dystrophy (DMD) and special drug designation for Duchenne muscular dystrophy (DMD) therapeutics will lead to sizable demand in the market.

The report on the Duchenne muscular dystrophy (DMD) therapeutics market covers the following areas:

Duchenne muscular dystrophy (DMD) therapeutics market sizing
Duchenne muscular dystrophy (DMD) therapeutics market forecast
Duchenne muscular dystrophy (DMD) therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Duchenne muscular dystrophy (DMD) therapeutics market vendors that include BioMarin Pharmaceutical Inc., Capricor Therapeutics Inc., CRISPR Therapeutics AG, CVS Health Corp., Daiichi Sankyo Co. Ltd., Editas Medicine Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Italfarmaco Holding SPA, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., PTC Therapeutics Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, Solid Biosciences Inc., The Cleveland Clinic Foundation, Vertex Pharmaceuticals Inc., and Wave Life Sciences Ltd. Also, the Duchenne muscular dystrophy (DMD) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global duchenne muscular dystrophy (DMD) therapeutics market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global duchenne muscular dystrophy (dmd) therapeutics market 2017 - 2021 ($ million)
4.2 Type Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
4.3 Distribution Channel Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

6.1 Market segments
Exhibit 30: Chart on Type - Market share 2022-2027 (%)
Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Biologics - Market size and forecast 2022-2027
Exhibit 34: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Biologics - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
6.4 Small molecules - Market size and forecast 2022-2027
Exhibit 38: Chart on Small molecules - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Small molecules - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Small molecules - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Small molecules - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Type
Exhibit 42: Market opportunity by Type ($ million)
Exhibit 43: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
Exhibit 44: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibit 45: Data Table on Distribution Channel - Market share 2022-2027 (%)
7.2 Comparison by Distribution Channel
Exhibit 46: Chart on Comparison by Distribution Channel
Exhibit 47: Data Table on Comparison by Distribution Channel
7.3 Offline - Market size and forecast 2022-2027
Exhibit 48: Chart on Offline - Market size and forecast 2022-2027 ($ million)
Exhibit 49: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
Exhibit 50: Chart on Offline - Year-over-year growth 2022-2027 (%)
Exhibit 51: Data Table on Offline - Year-over-year growth 2022-2027 (%)
7.4 Online - Market size and forecast 2022-2027
Exhibit 52: Chart on Online - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on Online - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on Online - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on Online - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Distribution Channel
Exhibit 56: Market opportunity by Distribution Channel ($ million)
Exhibit 57: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 59: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 61: Chart on Geographic comparison
Exhibit 62: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 65: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 66: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 79: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 83: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 UK - Market size and forecast 2022-2027
Exhibit 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.10 Canada - Market size and forecast 2022-2027
Exhibit 91: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.11 China - Market size and forecast 2022-2027
Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 99: Market opportunity By Geographical Landscape ($ million)
Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 101: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 103: Overview on factors of disruption
11.4 Industry risks
Exhibit 104: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 105: Vendors covered
12.2 Market positioning of vendors
Exhibit 106: Matrix on vendor position and classification
12.3 Capricor Therapeutics Inc.
Exhibit 107: Capricor Therapeutics Inc. - Overview
Exhibit 108: Capricor Therapeutics Inc. - Product/Service
Exhibit 109: Capricor Therapeutics Inc. - Key offerings
12.4 CRISPR Therapeutics AG
Exhibit 110: CRISPR Therapeutics AG - Overview
Exhibit 111: CRISPR Therapeutics AG - Product/Service
Exhibit 112: CRISPR Therapeutics AG - Key offerings
12.5 Daiichi Sankyo Co. Ltd.
Exhibit 113: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 114: Daiichi Sankyo Co. Ltd. - Product/Service
Exhibit 115: Daiichi Sankyo Co. Ltd. - Key news
Exhibit 116: Daiichi Sankyo Co. Ltd. - Key offerings
12.6 Editas Medicine Inc.
Exhibit 117: Editas Medicine Inc. - Overview
Exhibit 118: Editas Medicine Inc. - Product/Service
Exhibit 119: Editas Medicine Inc. - Key offerings
12.7 F. Hoffmann La Roche Ltd.
Exhibit 120: F. Hoffmann La Roche Ltd. - Overview
Exhibit 121: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 122: F. Hoffmann La Roche Ltd. - Key news
Exhibit 123: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 124: F. Hoffmann La Roche Ltd. - Segment focus
12.8 Italfarmaco Holding SPA
Exhibit 125: Italfarmaco Holding SPA - Overview
Exhibit 126: Italfarmaco Holding SPA - Product/Service
Exhibit 127: Italfarmaco Holding SPA - Key offerings
12.9 Nippon Shinyaku Co. Ltd.
Exhibit 128: Nippon Shinyaku Co. Ltd. - Overview
Exhibit 129: Nippon Shinyaku Co. Ltd. - Business segments
Exhibit 130: Nippon Shinyaku Co. Ltd. - Key offerings
Exhibit 131: Nippon Shinyaku Co. Ltd. - Segment focus
12.10 Otsuka Holdings Co. Ltd.
Exhibit 132: Otsuka Holdings Co. Ltd. - Overview
Exhibit 133: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 134: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 135: Otsuka Holdings Co. Ltd. - Segment focus
12.11 Pfizer Inc.
Exhibit 136: Pfizer Inc. - Overview
Exhibit 137: Pfizer Inc. - Product/Service
Exhibit 138: Pfizer Inc. - Key news
Exhibit 139: Pfizer Inc. - Key offerings
12.12 PTC Therapeutics Inc.
Exhibit 140: PTC Therapeutics Inc. - Overview
Exhibit 141: PTC Therapeutics Inc. - Product/Service
Exhibit 142: PTC Therapeutics Inc. - Key offerings
12.13 Santhera Pharmaceuticals Holding AG
Exhibit 143: Santhera Pharmaceuticals Holding AG - Overview
Exhibit 144: Santhera Pharmaceuticals Holding AG - Product/Service
Exhibit 145: Santhera Pharmaceuticals Holding AG - Key offerings
12.14 Sarepta Therapeutics Inc
Exhibit 146: Sarepta Therapeutics Inc - Overview
Exhibit 147: Sarepta Therapeutics Inc - Product/Service
Exhibit 148: Sarepta Therapeutics Inc - Key offerings
12.15 Solid Biosciences Inc.
Exhibit 149: Solid Biosciences Inc. - Overview
Exhibit 150: Solid Biosciences Inc. - Product/Service
Exhibit 151: Solid Biosciences Inc. - Key offerings
12.16 The Cleveland Clinic Foundation
Exhibit 152: The Cleveland Clinic Foundation - Overview
Exhibit 153: The Cleveland Clinic Foundation - Product/Service
Exhibit 154: The Cleveland Clinic Foundation - Key offerings
12.17 Wave Life Sciences Ltd.
Exhibit 155: Wave Life Sciences Ltd. - Overview
Exhibit 156: Wave Life Sciences Ltd. - Product/Service
Exhibit 157: Wave Life Sciences Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 158: Inclusions checklist
Exhibit 159: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 160: Currency conversion rates for US$
13.4 Research methodology
Exhibit 161: Research methodology
Exhibit 162: Validation techniques employed for market sizing
Exhibit 163: Information sources
13.5 List of abbreviations
Exhibit 164: List of abbreviations

List of Exhibits

Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 18: Historic Market Size - Data Table on global duchenne muscular dystrophy (dmd) therapeutics market 2017 - 2021 ($ million)
Exhibits 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
Exhibits 20: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2022 and 2027
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 29: Chart on Market condition - Five forces 2022 and 2027
Exhibits 30: Chart on Type - Market share 2022-2027 (%)
Exhibits 31: Data Table on Type - Market share 2022-2027 (%)
Exhibits 32: Chart on Comparison by Type
Exhibits 33: Data Table on Comparison by Type
Exhibits 34: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
Exhibits 35: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
Exhibits 36: Chart on Biologics - Year-over-year growth 2022-2027 (%)
Exhibits 37: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
Exhibits 38: Chart on Small molecules - Market size and forecast 2022-2027 ($ million)
Exhibits 39: Data Table on Small molecules - Market size and forecast 2022-2027 ($ million)
Exhibits 40: Chart on Small molecules - Year-over-year growth 2022-2027 (%)
Exhibits 41: Data Table on Small molecules - Year-over-year growth 2022-2027 (%)
Exhibits 42: Market opportunity by Type ($ million)
Exhibits 43: Data Table on Market opportunity by Type ($ million)
Exhibits 44: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibits 45: Data Table on Distribution Channel - Market share 2022-2027 (%)
Exhibits 46: Chart on Comparison by Distribution Channel
Exhibits 47: Data Table on Comparison by Distribution Channel
Exhibits 48: Chart on Offline - Market size and forecast 2022-2027 ($ million)
Exhibits 49: Data Table on Offline - Market size and forecast 2022-2027 ($ million)
Exhibits 50: Chart on Offline - Year-over-year growth 2022-2027 (%)
Exhibits 51: Data Table on Offline - Year-over-year growth 2022-2027 (%)
Exhibits 52: Chart on Online - Market size and forecast 2022-2027 ($ million)
Exhibits 53: Data Table on Online - Market size and forecast 2022-2027 ($ million)
Exhibits 54: Chart on Online - Year-over-year growth 2022-2027 (%)
Exhibits 55: Data Table on Online - Year-over-year growth 2022-2027 (%)
Exhibits 56: Market opportunity by Distribution Channel ($ million)
Exhibits 57: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 59: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 60: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 61: Chart on Geographic comparison
Exhibits 62: Data Table on Geographic comparison
Exhibits 63: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 64: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 65: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits 66: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits 67: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 68: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 69: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 70: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 71: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 72: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 73: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 74: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 75: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 76: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 77: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 78: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 79: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits 80: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits 81: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits 82: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits 83: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 84: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits 85: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 86: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 89: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits 90: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits 91: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits 92: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits 93: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 94: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 95: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits 97: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits 98: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits 99: Market opportunity By Geographical Landscape ($ million)
Exhibits 100: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 101: Impact of drivers and challenges in 2022 and 2027
Exhibits 102: Overview on Criticality of inputs and Factors of differentiation
Exhibits 103: Overview on factors of disruption
Exhibits 104: Impact of key risks on business
Exhibits 105: Vendors covered
Exhibits 106: Matrix on vendor position and classification
Exhibits 107: Capricor Therapeutics Inc. - Overview
Exhibits 108: Capricor Therapeutics Inc. - Product/Service
Exhibits 109: Capricor Therapeutics Inc. - Key offerings
Exhibits 110: CRISPR Therapeutics AG - Overview
Exhibits 111: CRISPR Therapeutics AG - Product/Service
Exhibits 112: CRISPR Therapeutics AG - Key offerings
Exhibits 113: Daiichi Sankyo Co. Ltd. - Overview
Exhibits 114: Daiichi Sankyo Co. Ltd. - Product/Service
Exhibits 115: Daiichi Sankyo Co. Ltd. - Key news
Exhibits 116: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibits 117: Editas Medicine Inc. - Overview
Exhibits 118: Editas Medicine Inc. - Product/Service
Exhibits 119: Editas Medicine Inc. - Key offerings
Exhibits 120: F. Hoffmann La Roche Ltd. - Overview
Exhibits 121: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 122: F. Hoffmann La Roche Ltd. - Key news
Exhibits 123: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 124: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 125: Italfarmaco Holding SPA - Overview
Exhibits 126: Italfarmaco Holding SPA - Product/Service
Exhibits 127: Italfarmaco Holding SPA - Key offerings
Exhibits 128: Nippon Shinyaku Co. Ltd. - Overview
Exhibits 129: Nippon Shinyaku Co. Ltd. - Business segments
Exhibits 130: Nippon Shinyaku Co. Ltd. - Key offerings
Exhibits 131: Nippon Shinyaku Co. Ltd. - Segment focus
Exhibits 132: Otsuka Holdings Co. Ltd. - Overview
Exhibits 133: Otsuka Holdings Co. Ltd. - Business segments
Exhibits 134: Otsuka Holdings Co. Ltd. - Key offerings
Exhibits 135: Otsuka Holdings Co. Ltd. - Segment focus
Exhibits 136: Pfizer Inc. - Overview
Exhibits 137: Pfizer Inc. - Product/Service
Exhibits 138: Pfizer Inc. - Key news
Exhibits 139: Pfizer Inc. - Key offerings
Exhibits 140: PTC Therapeutics Inc. - Overview
Exhibits 141: PTC Therapeutics Inc. - Product/Service
Exhibits 142: PTC Therapeutics Inc. - Key offerings
Exhibits 143: Santhera Pharmaceuticals Holding AG - Overview
Exhibits 144: Santhera Pharmaceuticals Holding AG - Product/Service
Exhibits 145: Santhera Pharmaceuticals Holding AG - Key offerings
Exhibits 146: Sarepta Therapeutics Inc - Overview
Exhibits 147: Sarepta Therapeutics Inc - Product/Service
Exhibits 148: Sarepta Therapeutics Inc - Key offerings
Exhibits 149: Solid Biosciences Inc. - Overview
Exhibits 150: Solid Biosciences Inc. - Product/Service
Exhibits 151: Solid Biosciences Inc. - Key offerings
Exhibits 152: The Cleveland Clinic Foundation - Overview
Exhibits 153: The Cleveland Clinic Foundation - Product/Service
Exhibits 154: The Cleveland Clinic Foundation - Key offerings
Exhibits 155: Wave Life Sciences Ltd. - Overview
Exhibits 156: Wave Life Sciences Ltd. - Product/Service
Exhibits 157: Wave Life Sciences Ltd. - Key offerings
Exhibits 158: Inclusions checklist
Exhibits 159: Exclusions checklist
Exhibits 160: Currency conversion rates for US$
Exhibits 161: Research methodology
Exhibits 162: Validation techniques employed for market sizing
Exhibits 163: Information sources
Exhibits 164: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global Duchenne muscular dystrophy (DMD) therapeutics market: BioMarin Pharmaceutical Inc., Capricor Therapeutics Inc., CRISPR Therapeutics AG, CVS Health Corp., Daiichi Sankyo Co. Ltd., Editas Medicine Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Italfarmaco Holding SPA, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., PTC Therapeutics Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc, Solid Biosciences Inc., The Cleveland Clinic Foundation, Vertex Pharmaceuticals Inc., and Wave Life Sciences Ltd.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is a strong pipeline of Duchenne muscular dystrophy (DMD) therapeutics.'

According to the report, one of the major drivers for this market is the high unmet need among patients with Duchenne muscular dystrophy (DMD).

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

BioMarin Pharmaceutical Inc.
Capricor Therapeutics Inc.
CRISPR Therapeutics AG
CVS Health Corp.
Daiichi Sankyo Co. Ltd.
Editas Medicine Inc.
Eli Lilly and Co.
F. Hoffmann La Roche Ltd.
FibroGen Inc.
Italfarmaco Holding SPA
Nippon Shinyaku Co. Ltd.
Otsuka Holdings Co. Ltd.
Pfizer Inc.
PTC Therapeutics Inc.
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
Solid Biosciences Inc.
The Cleveland Clinic Foundation
Vertex Pharmaceuticals Inc.
Wave Life Sciences Ltd.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2439EUR$2,500USD£2,082GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€3902EUR$4,000USD£3,331GBP

The Duchenne muscular dystrophy (DMD) therapeutics market is segmented as below:

By Type

By Distribution Channel

By Geographical Landscape

The report on the Duchenne muscular dystrophy (DMD) therapeutics market covers the following areas:

Table of Contents

Executive Summary

Companies Mentioned (Partial List)

Related Topics

Related Reports

Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2024

Duchenne Muscular Dystrophy Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Global Duchenne Muscular Dystrophy Drugs Market by Drug Type, by Distribution Channel, and By Region

Duchenne Muscular Dystrophy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Duchenne Muscular Dystrophy Drugs - Global Strategic Business Report